Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the
epidemiology of LN and its clinical presentation have been changing. However, even …

The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …

Objective To update the 2012 EULAR/ERA–EDTA recommendations for the management of
lupus nephritis (LN). Methods Following the EULAR standardised operating procedures, a …

Juvenile-onset systemic lupus erythematosus (jSLE) accounts for up to 20% of all SLE
patients. Key differences between juvenile-and adult-onset (aSLE) disease include higher …

Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can present as an
isolated skin disease or as a manifestation within the spectrum of systemic lupus …

Objective To investigate predictors of response, remission, low disease activity, damage,
and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were …

Objectives To evaluate changes in demographic, clinical and histological presentation, and
prognosis of lupus nephritis (LN) over time. Patients and methods We studied a multicentre …

Autoimmune rheumatic diseases are characterised by an abnormal immune system
response, complement activation, cytokines dysregulation and inflammation. In last years …

Belimumab (Benlysta®) is a human immunoglobulin G1λ monoclonal antibody that inhibits
the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent …

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that predominately
affects women. It is characterised by a broad spectrum of clinical manifestations, however, its …